New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2013
07:33 EDTATRSAntares Pharma'a Otrexup NDA accepted by FDA
Antares Pharma announced that the New Drug Application for Otrexup, a potential new product for the subcutaneous delivery of methotrexate using Medi-Jet technology, has been accepted by the FDA indicating that the application is sufficiently complete to permit a substantive review. Otrexup is being developed for self-administration of MTX to enhance the treatment of rheumatoid arthritis, poly-articular-course juvenile RA and psoriasis. The FDA has assigned a target date of October 14, ten months from the official NDA filing, to complete its review of the NDA.
News For ATRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 18, 2015
10:01 EDTATRSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:03 EDTATRSAntares Pharma initiated with an Overweight at Piper Jaffray
Target $3.50.
May 11, 2015
07:20 EDTATRSAntares Pharma reports Q1 EPS (5c), consensus (4c)
Reports Q1 revenue $8.3M, consensus $9.32M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use